Overview

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai HyaMab Biotech Co.,Ltd.
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins